UniProt ID | PHF5A_HUMAN | |
---|---|---|
UniProt AC | Q7RTV0 | |
Protein Name | PHD finger-like domain-containing protein 5A | |
Gene Name | PHF5A | |
Organism | Homo sapiens (Human). | |
Sequence Length | 110 | |
Subcellular Localization | Nucleus . Nucleus speckle . | |
Protein Description | Involved with the PAF1 complex (PAF1C) in transcriptional elongation by RNA polymerase II, and in regulation of development and maintenance of embryonic stem cell (ESC) pluripotency. Required for maintenance of ESCs self-renewal and cellular reprogramming of stem cells. Maintains pluripotency by recruiting and stabilizing PAF1C on pluripotency genes loci, and by regulating the expression of the pluripotency genes. Regulates the deposition of elongation-associated histone modifications, including dimethylated histone H3 'Lys-79' (H3K79me2) and trimethylated histone H3 'Lys-36' (H3K36me3), on PAF1C targets, self-renewal and pluripotency genes. Regulates RNA polymerase II promoter-proximal pause release of the PAF1C targets and self-renewal genes, and the levels of elongating ('Ser-2' phosphorylated) RNA polymerase II in their gene bodies. Regulates muscle specification in adult stem cells by stabilizing PAF1C in chromatin to promote myogenic differentiation (By similarity). Involved in pre-mRNA splicing as a component of the splicing factor SF3B complex. [PubMed: 27720643] | |
Protein Sequence | MAKHHPDLIFCRKQAGVAIGRLCEKCDGKCVICDSYVRPCTLVRICDECNYGSYQGRCVICGGPGVSDAYYCKECTIQEKDRDGCPKIVNLGSSKTDLFYERKKYGFKKR | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
3 | Malonylation | -----MAKHHPDLIF -----CCCCCCCEEE | 40.94 | 26320211 | |
3 | Ubiquitination | -----MAKHHPDLIF -----CCCCCCCEEE | 40.94 | 19608861 | |
3 | 2-Hydroxyisobutyrylation | -----MAKHHPDLIF -----CCCCCCCEEE | 40.94 | - | |
3 | Acetylation | -----MAKHHPDLIF -----CCCCCCCEEE | 40.94 | 19608861 | |
13 | Ubiquitination | PDLIFCRKQAGVAIG CCEEEEEHHCCCHHH | 45.76 | - | |
13 | 2-Hydroxyisobutyrylation | PDLIFCRKQAGVAIG CCEEEEEHHCCCHHH | 45.76 | - | |
25 | Acetylation | AIGRLCEKCDGKCVI HHHHHHHHCCCEEEE | 36.31 | 23749302 | |
25 | 2-Hydroxyisobutyrylation | AIGRLCEKCDGKCVI HHHHHHHHCCCEEEE | 36.31 | - | |
29 | Acetylation | LCEKCDGKCVICDSY HHHHCCCEEEEECCC | 16.45 | 25953088 | |
35 | Phosphorylation | GKCVICDSYVRPCTL CEEEEECCCCCCCEE | 22.55 | 28152594 | |
36 | Phosphorylation | KCVICDSYVRPCTLV EEEEECCCCCCCEEE | 6.29 | 28152594 | |
41 | Phosphorylation | DSYVRPCTLVRICDE CCCCCCCEEEEECCC | 30.85 | 28152594 | |
51 | Phosphorylation | RICDECNYGSYQGRC EECCCCCCCCCCCEE | 21.07 | 28152594 | |
53 | Phosphorylation | CDECNYGSYQGRCVI CCCCCCCCCCCEEEE | 12.15 | 28152594 | |
54 | Phosphorylation | DECNYGSYQGRCVIC CCCCCCCCCCEEEEC | 15.60 | 28152594 | |
67 | Phosphorylation | ICGGPGVSDAYYCKE ECCCCCCCCEEEEEC | 23.57 | 28152594 | |
70 | Phosphorylation | GPGVSDAYYCKECTI CCCCCCEEEEECCCC | 17.87 | 28152594 | |
71 | Phosphorylation | PGVSDAYYCKECTIQ CCCCCEEEEECCCCC | 9.96 | 28152594 | |
73 | Ubiquitination | VSDAYYCKECTIQEK CCCEEEEECCCCCEE | 39.44 | - | |
73 | Acetylation | VSDAYYCKECTIQEK CCCEEEEECCCCCEE | 39.44 | 23749302 | |
80 | Acetylation | KECTIQEKDRDGCPK ECCCCCEECCCCCCC | 41.51 | 25953088 | |
87 | Ubiquitination | KDRDGCPKIVNLGSS ECCCCCCCEEEECCC | 64.46 | - | |
87 | Acetylation | KDRDGCPKIVNLGSS ECCCCCCCEEEECCC | 64.46 | 26051181 | |
93 | Phosphorylation | PKIVNLGSSKTDLFY CCEEEECCCCHHHHH | 31.65 | 28450419 | |
94 | Phosphorylation | KIVNLGSSKTDLFYE CEEEECCCCHHHHHH | 37.46 | 28450419 | |
95 | Malonylation | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | 26320211 | |
95 | Sumoylation | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | - | |
95 | Acetylation | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | 26051181 | |
95 | Ubiquitination | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | 21890473 | |
95 | 2-Hydroxyisobutyrylation | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | - | |
95 | Sumoylation | IVNLGSSKTDLFYER EEEECCCCHHHHHHH | 47.99 | - | |
96 | Phosphorylation | VNLGSSKTDLFYERK EEECCCCHHHHHHHH | 39.62 | 28450419 | |
100 | Phosphorylation | SSKTDLFYERKKYGF CCCHHHHHHHHHHCC | 23.32 | 28796482 | |
105 | Phosphorylation | LFYERKKYGFKKR-- HHHHHHHHCCCCC-- | 30.72 | 26074081 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PHF5A_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PHF5A_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PHF5A_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
SF3B1_HUMAN | SF3B1 | physical | 22939629 | |
SF3B3_HUMAN | SF3B3 | physical | 22939629 | |
RU2A_HUMAN | SNRPA1 | physical | 22939629 | |
SF3B4_HUMAN | SF3B4 | physical | 22939629 | |
RU2B_HUMAN | SNRPB2 | physical | 22939629 | |
SF3B6_HUMAN | SF3B6 | physical | 22939629 | |
SF3B5_HUMAN | SF3B5 | physical | 22939629 | |
SF3B2_HUMAN | SF3B2 | physical | 22939629 | |
YBOX1_HUMAN | YBX1 | physical | 22939629 | |
ROA1_HUMAN | HNRNPA1 | physical | 22939629 | |
SFPQ_HUMAN | SFPQ | physical | 22939629 | |
PRP31_HUMAN | PRPF31 | physical | 22939629 | |
RBM25_HUMAN | RBM25 | physical | 22939629 | |
S10AA_HUMAN | S100A10 | physical | 22939629 | |
PRP31_HUMAN | PRPF31 | physical | 22365833 | |
SF3B4_HUMAN | SF3B4 | physical | 26344197 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3, AND MASS SPECTROMETRY. |